Drugs / KM-023
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01348516 | May 2011 → Mar 2012 | HIV infectious disease | Kainos Medicine Inc. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07631897 | Jun 2026 → Jun 2028 expected | HIV infectious disease, tuberculosis | Shanghai Public Health Clinical Center | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07090889 Comparator | Jul 2025 → Nov 2026 expected | Olmsted syndrome | Orvida Pharma | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KM-023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07090889 ↗ |
| Known as | Ainuovirine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07631897 ↗ |
| Route | Oral | “dosed orally” NCT01348516 ↗ |